Position of the Transparency Council – Opdivo (niwolumab)
At its meeting on 22 August 2022 the Transparency Council adopted Position No. 78/2022 on the evaluation of drug: Opdivo (nivolumab) under the drug programme: ,,Treatment of patients with advanced colorectal cancer (ICD-10: C18 – C20)”.
Publication in Public Information Bulletin (BIP)